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Ivermectin is an effective drug for the treatment of human onchocerciasis, a disease caused by
the parasitic filarial nematode Onchocerca volvulus. When humans are treated, the microfilariae
normally found in the skin are rapidly and very nearly completely eliminated. Nonetheless, after a
delay, microfilariae gradually reappear in the skin. This study is concerned with the causes of this
delay. Hypotheses are tested by comparing the results of model calculations with skin microfilaria
counts collected from 114 patients during a trial of five annual treatments in the focus area of
Asubende, Ghana. The results obtained strongly suggest that annual treatment with ivermectin
causes an irreversible decline in microfilariae production of ~30%/treatment. This result has im-
portant implications for public health strategies designed to eliminate onchocerciasis as a significant
health hazard.
The registration ofthe anthelminthic drug ivermectin (Mecti-
zan; Merck, Rahway, NJ) in 1987 was a landmark in the control
of human onchocerciasis or river blindness, a parasitic disease
caused by the filarial nematode Onchocerca volvulus. Oral ad-
ministration in a standard dose of 150-200 j.Lg/kg of body
weight is followed by rapid elimination of microfilariae (Mf)
from the skin and gradual reduction of ocular Mf levels [1].
Side effects are generally mild. This makes ivermectin a better
therapeutic option than diethylcarbamazine, which is often ac-
companied by severe Mazotti reactions and ocular damage.
Ivermectin also produces a longer suppression ofMfrepopula-
tion of the skin [2, 3]. To explain this difference, which was
obvious in all studies done so far, the effects of ivermectin on
adult parasites were studied.
Adult female parasites in treated persons show an interrup-
tion of the normal embryogenesis, but after a single treatment,
this appears to be reversible for most of the worms [4, 5].
Excess worm mortality was not observed after a single treat-
ment [1, 2, 6], although significant numbers of dead and mori-
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bund worms were reported after multiple treatments at intervals
between 2 weeks and 6 months [6- 11]. Furthermore, after
multiple treatments, the reproductive activity of the surviving
worms was markedly reduced. The suppression of Mf produc-
tion persisted 1.5 years after five 6-monthly doses [12], which
suggests the existence of irreversible effects of the drug.
An important question in view of the limited resources avail-
able to health services in developing countries is whether these
findings for shorter treatment intervals are applicable to regi-
mens with intervals of 1 year, the current practice in nearly all
onchocerciasis control programs [13]. In this study, we ad-
dressed this question by analyzing data from a large commu-
nity-based study of annual treatment in a region with hyperen-
demic onchocerciasis (Asubende, Ghana), organized by the
Onchocerciasis Control Programme in West Africa (OCP)
[14-17].
The available data consist of Mf counts in skin snips from
persons who were repeatedly surveyed over ~5 years during
treatment. We investigated whether the observed changes in
Mf counts could be explained if ivermectin had only transient
effects on adult worms or whether long-term irreversible effects
on the fecundity of adult worms were required to explain the
data. In addition to the direct effect in individual patients,
community treatment with ivermectin also reduces the level of
transmission in the area (indirect effect) [14, 17]. To take both
effects into account, we did the investigation with the aid of
an epidemiologic model of onchocerciasis transmission.
Material and Methods
Study population. The Asubende region is along the lower
reaches of the Pru River, just west of Lake Volta. OCP initiated a
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program to control the vector of 0. volvulus, the blackfly Simulium
damnosum, in this river basin in January 1986. Flies have been
collected since 1979 to assess the vector biting rate and the vector
infectivity. A clinical survey was done in September 1987 among
796 persons living in a cluster of three villages in the middle of
the area. Both entomologic and clinical findings revealed that the
savanna form of 0. volvulus is hyperendemic in this area. Skin
Mf densities were among the highest encountered in the OCP area
[14]. The community trial of annual ivermectin treatment was
started in October 1987.
In the present analysis we use data consisting of counts of Mf
in skin snips that were collected during the period covered by the
first five treatments (1987 -1991). The organization of the trial,
the trends in skin Mf densities, and the joint effect ofvector control
and ivermectin treatment on the transmission potential of the flies
have been described elsewhere [14, 17]. Treatment dose varied
between 130 and 200 j.Lg/kg.
From the 796 persons examined at the baseline survey in 1987,
we selected 2 cohorts that comprised a total of 114 adults. Cohort
1 is 78 persons who were treated in all five rounds and were
examined in all eight follow-up surveys. These surveys were done
at 4 and 12 months after the first two treatments, 5 and 12 months
after the third, 11 months after the fourth, and 6 months after the
fifth treatment. Cohort 2 is 36 persons who were treated in the
first but not in the second round and who were examined 24 months
after the first treatment. We restricted the study to adults to exclude
the confounding effect of ageing; only for older ages do we expect
a constant infection level [18].
Model and hypotheses. We tested two hypotheses: The first
(H I) assumes that treatment has only a transient effect on the
Mf production of female worms; the second (H2 ) assumes that
ivermectin's effect is partially irreversible, manifested by a perma-
nently reduced fecundity ofthe worms in a treated patient. Hypoth-
eses were tested with the stochastic microsimulation model ON-
CHOSIM. This model simulates the life histories of hypothetical
individual persons (birth, acquisition of parasites, death) and indi-
vidual parasites (maturation, mating, production of Mf, death) and
can be used to describe and test effects of ivermectin on a patient
level. ONCHOSIM further allows for a detailed simulation of
control strategies. The model simulates ivermectin treatments and
surveys at the same times as in the field. It also mimics the vector
control activities used in the Asubende area, which strongly af-
fected the transmission potential of the flies both before and during
the trial [17]. The microsimulation method makes it possible to
select persons from the simulated population who satisfy the same
criteria used for selecting the cohorts and whose Mf counts before
the first treatment are the same as those of the cohorts.
A full description of ONCHOSIM and the validation of the
model is given elsewhere [19-22]. Here we will present only those
relationships and parameters that are directly relevant to the effects
of ivermectin.
Modeling the effects of ivermectin. An assumption used
throughout the analysis is that a treatment with ivermectin instantly
eliminates all Mf in a person, except in 3% of treatments, which
totally fail as a result of malabsorption (e.g., diarrhea, vomiting)
[23]. Under the first hypothesis (HI), each treatment further causes
a transient interruption of the normal release of Mf by adult female
parasites. During a recovery period, the rate of Mf production
increases from zero to the pretreatment level. We explicitly test
whether this increase is linear or not.
The same assumption regarding the initial effect of treatment is
made under the alternative hypothesis (H2) . However, in this case,
we assume that worms do not recover to their full capacity to
release Mf, but that this capacity is irreversibly reduced with a
fraction called "productivity reduction." This productivity reduc-
tion affects all worms in a patient.
Since the available data do not reveal much about the exact
mechanism of a (possible) irreversible effect, we also tested an
alternative form of the second hypothesis (H/), in which a certain
fraction of worms loses their fecundity totally, while the others
recover completely. This fraction is called "fecundity loss."
Between-treatment (and within-patient) variation in recovery pe-
riod, productivity reduction, and fecundity loss is governed by
effect variability, defined as the variation coefficient (i.e., the quo-
tient of SD and mean) of treatment effects. The time between
treatment and the stabilization of the Mf density in skin is deter-
mined not only by the effect of ivermectin on adult worms but
also by the life span of Mf. This Mf life span is estimated when
the hypotheses are tested. A mathematical description of the sub-
model for the effect of ivermectin treatment is given in the Appen-
dix. A graphic representation of the hypotheses and roles of the
model parameters are provided in figure 1.
Hypothesis testing. To test hypotheses and quantify model pa-
rameters, both observed and calculated survey results were repre-
sented as frequency distributions of Mf counts, using the classes
shown in figure 2. The agreement between observations and predic-
tions was determined by calculating a total X 2 for all follow-up
surveys of cohorts 1 and 2. Some adjacent skin snip count classes
were combined so that the number of individuals was at least 51
class. Estimating parameters for a specific hypothesis was achieved
by minimizing X2 using a downhill simplex method [24]. The
goodness-of-fit implied by the minimum X2 was quantified by the
P value of the X2 distribution with 16 df (only transient effects)
or 15 df(also irreversible effects). Generally, P < .05 indicates a
poor fit and suggests rejection of the underlying hypothesis.
After model parameters were estimated, a 95% confidence inter-
val (CI) of a particular estimate was determined by searching
around the original estimate for values resulting in X2 = 3.84 units
(0.95 point of X2 distribution with 1 df) higher than the minimum.
For each of the values tried, the other ivermectin-related parame-
ters were reestimated by minimizing X 2 •
Results
For the baseline and follow-up surveys, the number ofMfper
skin snip observed in the 2 cohorts are shown in the frequency
distributions in figure 2. Considering the data from cohort 1,
both short-term and longer-lasting effects of treatment were
apparent. At 4-6 months after each treatment, the distribution
was consistently skewed toward low Mf counts. Although after
11-12 months the distributions again tended to the pretreat-
ment shape, it is clear that, as the number of treatments in-
creased, the peak of the distributions shifted to lower counts:
~32-64 Mf/snip I year after the first treatment to 4-16 Mf/
snip I year after the fourth round. A long-term effect was also
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recovery period (Tr)
Figure 1. Schematic representation of hypotheses tested. Each
graph shows rate of microfilaria production (r) of parasite as function
of time (t) after single treatment. Moment of treatment is indicated
with vertical arrow below x axis. In hypothesis HI, no irreversible
effect is assumed; treatment only results in recovery period of length
Tr. According to hypothesis Hz, productivity after recovery period is
permanently reduced (factor d); with Hz', fraction m of worms totally
loses fecundity. See Appendix for further explanation of symbols.
t
t
t
total fecundity loss for
fraction m of worms
(others as H1)
production rate accelerated (see the nonlinear trends in figure
1; s = 1.5, Appendix). Both the recovery period and the Mf life
span are inversely related to the speed ofthe Mfrepopulation of
the skin after treatment. Therefore, apparently to compensate
for the lack of irreversible effect, under the first hypothesis,
both parameters were estimated at significantly higher values.
The effect of treatment varied considerably between treat-
ments. The value of 0.52 estimated for effect variability (H2)
means that one-fourth of treatments resulted in a recovery pe-
riod of <6 months and a productivity reduction of <20%. By
contrast, for another one-fourth these numbers were > 14
months and >47%, respectively. Half of treatments had an
intermediate efficacy.
Model results, assuming irreversible effects, were compared
with the observations (figure 2, open bars). There were no
systematic differences between prediction and observations for
cohort 1 (figure 2A). The lowest and highest Mf count catego-
ries of the follow-up survey of cohort 2 were underestimated
(figure 2B), suggesting more treatment variability in this co-
hort. For cohort 1, model predictions under both hypotheses
are shown in figure 3. Here, predictions and observations are
represented as the geometric mean Mf count. Only the pretreat-
ment and follow-up surveys at 11-12 months are shown (i.e.,
just before another treatment). Under both hypotheses, the geo-
metric mean Mf counts decline sharply after the first treatment
and more gradually thereafter. However, the slope of the line
connecting the follow-up surveys is much steeper if irreversible
changes are considered (H 2) . Under HI, the Mf counts after
repeated treatment decline only because the transmission dy-
namics of the infection are disturbed by the combination of
treatment and vector control. This decline is too slow to fit the
observations.
observed in the data from cohort 2 (figure 2B); before treat-
ment, ----30% of the population had> 128 Mf/skin snip. Two
years after a single treatment this was only slightly > 15%.
We tested two hypotheses for explaining the data (figure 1).
The results are shown in table 1. For each hypothesis, estimates
of relevant parameters and goodness-of-fit (P values) are given.
HI, which assumed no irreversible effects of ivermectin, fits
poorly (P = .0013) and must be rejected. By contrast, a good
fit was obtained when an irreversible productivity reduction
for all worms was considered (H2 : P = .68). This productivity
reduction was ----35%/treatment (95% CI, 26%-40%). Assum-
ing another mechanism for the irreversible effect of treatment
(H/) did not lead to significantly different conclusions. Total
fecundity loss was ----28%/treatment, while the other parameter
estimates were about the same for H2 and H/. A model that
combines both types of irreversible effect (not shown) did not
produce a significantly better fit to the data. In such a model,
the combined loss of Mf production in a patient was ---- 32%/
treatment (95% CI, 22%-40%).
The irreversibly reduced level of Mf production was pre-
ceded by a recovery period of ---- 10 months during which the
Discussion
Our analysis of the results of five consecutive annual treat-
ments provides strong evidence that apart from killing Mf,
ivermectin reduces the viability of adult female parasites. The
trend in Mf counts was explained by the hypothesis that after
each treatment, Mf production gradually increases over 10
months (transient effect) and then reaches a plateau that re-
mains 32% lower than before treatment (irreversible effect;
combining H2 and H/).
The transient effect agrees with results of earlier studies,
which showed that in most parasites, the normal release of Mf
was interrupted after treatment, but 10-12 months later, Mf
production had largely been restored [4, 5, 25]. Although none
of these studies revealed excess mortality of worms from a
single treatment, after 1 year a considerable fraction (40% [5])
was not (yet) releasing Mf, which explains the considerable
delay in repopulation of the skin by Mf [1, 3,26-28]. In some
studies, even 2 years after treatment, Mf density was markedly
reduced [29, 30], although most persons had become Mf-posi-
tive again. Indeed, in cohort 2 (treated only once), the mean
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Figure 2. Frequency distributions of microfilarial (Mf) counts for pre- and posttreatment surveys. A, Cohort I, 78 patients treated 5 times
and examined 8 times. B, Cohort 2,36 patients treated once and examined 24 months later. Shaded bars = observations; open bars = predictions
based on hypothesis H2 (using parameter estimates of table I); x axes = lower boundaries of skin snip count classes; nos. in graphs = survey
order.
Mf density after 2 years was still less than half the pretreatment
level, suggesting a lasting effect.
On the other hand, as figure 3 makes clear, one must be
careful in drawing conclusions from decreasing Mf trends.
Also, without irreversible drug effects, the model predicts a
decrease (albeit insufficient) in Mf count at the follow-up sur-
veys at 11-12 months. This decrease is exclusively due to
the reduced transmission of the parasite as a consequence of
ivermectin treatment and (partial) vector control [17]. This
effect on the transmission was taken into account under the
assumption that the parasite larvae in flies originate from inhab-
itants of Asubende and will again be transmitted to them. Such
an assumption would not be valid in areas with migration of
flies, but Asubende is an isolated focus with a local transmis-
sion [14].
So far, irreversible effects of ivermectin have been observed
only after multiple treatments at intervals of ~ 6 months. In
patients who receive 4-12 doses at intervals of 2 weeks to 6
months, more dead or moribund female parasites are found
than in controls who receive no or only 1 treatment [5-7, 9,
10]. Excess worm mortality of 25%-33% is observed after 8-
11 doses at 3-month intervals [9]. Though these are significant
percentages, they are about equal to the irreversible effect we
found for each round of treatment. This suggests that killing of
worms is not the most important component of the irreversible
effect: 25% excess mortality after 8 treatments implies (only)
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Table 1. Parameter estimates and goodness-of-fit for the different hypotheses about the effect of
iverrnectin on the microfilaria (Mf) production of adult parasites..
Hypothesis*
Parameter H'2
Productivity reduction
Total fecundity loss
Recovery period (months)
Effect variability (coefficient of
variation)
Mf lifespan (months)
Goodness-of-fit (P[X 2])
19.0
0.87
14
.0013 [39]
35% (26%-40%)
lOA (7-16)
0.54 (004-0.7)
9 (4-12)
.68 [11.9]
28% (22%-35%)
10.7
0.52
10
042 [15.5]
NOTE. -, this parameter is not considered and thus has value of O. Nos. in parentheses are 95% confidence
intervals.
* See legend of figure 1 for description of hypotheses.
these estimates is caused by the different impact of the two
mechanisms on the Mf counts in persons with low worm loads.
If each treatment eliminates a certain fraction of productive
worms, then in such persons frequently no productive worm
is left (especially after repeated treatment) and, as a conse-
quence, the skin snip is negative (no Mt). In the simulated
population this leads to more skin snip-negative persons than
with an equal percentage of productivity reduction. This ex-
plains the (slightly) lower estimate for fecundity loss.
Other mechanisms also could cause both transient and irre-
versible changes. For example, some studies demonstrate a
significant reduction of the number of male worms [7, 9].
Although these lower counts may be the result of the ability
ofmale worms to leave nodules [31], it may at least temporarily
lead to reduced mating chances and a lower Mf output of
female worms. Hence, we cannot exclude that part of the effect
estimated for female worms should be attributed to males. It
is important to stress that the results of our analysis are based
on data collected during annual treatment using a dose of 130-
200 p,g/kg. Changes in treatment frequency or dose may lead
to other effects per treatment.
In all model calculations, we have assumed that variability
in treatment effect is exclusively between-treatment variability.
Two extensions that have been tested explicitly are effect-
variability between the worms in a patient and between-patient
variation of treatment effect (some patients systematically re-
spond well, others poorly). Neither extension affects our con-
clusion or produced a better fit. The absence ofbetween-patient
variability justifies the use of the X2 statistic for calculating
the goodness-of-fit (P) and determining CIs, the X2 assuming
independence between successive observations on the same
persons.
Our conclusions have important implications for the public
health impact of strategies based on annual ivermectin treat-
ment, which is the currently recommended regimen. In earlier
studies, we emphasized the potential of the drug for reducing
the burden of blindness [20, 32]. However, lack of sufficient
'87
Calendar year
5'----r----.------.----.------,
10
......... 3.5% excess mortality per treatment. Furthermore, 6 months
after the last dose (the longest follow-up in most studies), most
female worms had not yet resumed normal embryogenesis and
viability was markedly reduced. Recent investigations suggest
that recovery to full productivity after this short follow-up
period is unlikely or will take > 2 years [12].
The available data on Mf counts do not allow us to draw
inferences on the biologic mechanisms responsible for the irre-
versible treatment effect. The data are equally well fit by two
quite different mechanisms: an average productivity reduction
of 35% for all worms in a patient or the total loss of fecundity
by an average of 28% of the worms. The difference between
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Figure 3. Observed (+ ) and predicted geometric mean microfilaria
(Mf) counts (log scale) for pretreatment and 11-12 follow-up surveys
of cohort 1. Solid line = prediction based on hypothesis Hz (using
parameter estimates of table 1); dashed line = prediction based on
hypothesis HI'
JID 1995; 172 (July) Irreversible Effects of Ivennectin 209
follow-up data at that time meant that an irreversible effect of
treatment on adult worms could not be demonstrated. This was
the main cause of doubt about the potential of ivermectin for
transmission control and thus for our cautiousness in designat-
ing it as the successor of vector control.
Now this point of view merits reconsideration. If each treat-
ment leads to an irreversible reduction of fecundity by ~30%,
after five treatments, the loss will be >80% (not counting
reinfections). These results should stimulate the assessment of
the impact of higher doses on the viability of adult parasites.
Extrapolating to a longer period of annual treatment is less
straightforward; not everyone will be treated (a coverage of
65%-70% would be excellent in routine health care), and trans-
mission will continue (albeit on a lower level), causing new
infections. Preliminary computer simulation studies indicate
that, although the impact of long-term ivermectin regimens
is more pronounced than previously expected, the parasite is
unlikely to be eradicated within a period of 15 years of annual
treatment in an area where it is endemic.
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Appendix
Here we describe the model that combines hypotheses H2 and
Hz'. By making the appropriate simplifications, the models for H],
H2 , and H2 ' are obtained.
If m denotes the mean fraction total fecundity loss and vi) is the
effectiveness of treatment round i (i = 1, ...,5) in person}, then
fraction vi)m of the worms in person} will permanently cease Mf
production immediately after treatment i. vi) is a random variable,
which for each treatment i and each person} is generated from a
gamma probability distribution with a mean = 1.0 and a variation
coefficient equivalent to the effect variability. For female worms
in person} that do not lose fecundity after treatment i (a fraction,
1 - vi)m), the rate of Mf production rijk of each worm k at time t
after treatment is described by the following:
for t < vijTr.
for t ::=:: vijTr.
